Weil C
Curr Med Res Opin. 1986;10(1):25-51. doi: 10.1185/03007998609111089.
This paper reviews the safety data on bromocriptine administration for 1 to 10 years at daily doses of 1.25 to 80 mg in over 1100 patients with pituitary hormone overproduction (mainly from prolactinomas and growth-hormone producing adenomas), at daily doses of 3.75 to 170 mg in over 700 patients with Parkinson's disease, and at daily doses of 2.5 to 20 mg in 28 patients with various other conditions. In addition, information is provided on the safety for mother and child of bromocriptine administered at daily doses of 2.5 to 35 mg throughout gestation (54 pregnancies) or during its later stages (39 pregnancies). The side-effects of long-term bromocriptine treatment are usually no different from those seen during short-term treatment; most of them are relatively benign, and they have been shown in virtually all patients to be reversible. Bromocriptine appears to have no harmful effect on hepatic, renal, haematologic, or cardiac functions. It is considered that a hitherto unknown, severe though rare side-effect of bromocriptine is unlikely to be reported after such long experience.
本文回顾了1100多名垂体激素分泌过多患者（主要为催乳素瘤和生长激素分泌型腺瘤患者）服用溴隐亭1至10年的安全性数据，这些患者的日剂量为1.25至80毫克；700多名帕金森病患者服用溴隐亭的安全性数据，日剂量为3.75至170毫克；以及28名患有其他各种病症的患者服用溴隐亭的安全性数据，日剂量为2.5至20毫克。此外，还提供了在整个妊娠期（54例妊娠）或妊娠后期（39例妊娠）每日服用2.5至35毫克溴隐亭对母婴安全性的信息。长期服用溴隐亭的副作用通常与短期治疗时所见的副作用无异；大多数副作用相对较轻，而且几乎所有患者的副作用均可逆转。溴隐亭似乎对肝脏、肾脏、血液或心脏功能没有有害影响。考虑到有如此长期的用药经验， hitherto unknown，严重但罕见的溴隐亭副作用不太可能被报告。 （注：“hitherto unknown”此处直接保留英文，因为不确定其准确的中文表述且不影响整体理解）
